Chronic HIV-1 infection is associated with lower frequencies and functional impairment of mucosaassociated invariant T (MAIT) cells. We evaluated IL-7 treatment to restore MAIT cells in peripheral blood of chronically HIV-1-infected individuals on antiretroviral therapy. IL-7 led to increased relative and absolute levels of MAIT cells, and this expansion occurred primarily in the CD8 R subset. These results suggest that IL-7 may represent a therapeutic intervention for the restoration of MAIT cells in chronic HIV-1 infection.
Mucosa-associated invariant T (MAIT) cells represent a subset of unconventional, innate-like T cells that are abundant in healthy individuals, constituting 1-10% of peripheral blood T cells [1] and are present in mucosa, liver, and mesenteric lymph nodes [2] . MAIT cells are characterized by the expression of a semi-invariant Va7.2-carrying T-cell receptor (TCR), IL-18Ra, the promyelocytic leukemia zinc finger protein [1] , and high levels of CD161 and the alpha chain of the IL-7 receptor [2] .
The majority of MAIT cells is either CD8aa or CD8ab, with smaller CD4 þ /8 þ double-negative and CD4 þ populations [1] . MAIT cells recognize microbial vitamin B 2 biosynthetic intermediates presented by the nonclassical major histocompatibility complex-1-related protein 1 [3] , and respond to such antigens with production of proinflammatory cytokines [1] and cellular cytotoxicity [2, 3] . During chronic HIV-1 infection, there is a numerical and functional loss of MAIT cells that persists despite long-term antiretroviral therapy (ART) [2, 4] . Approaches to restore MAIT cells may improve mucosal and antibacterial immunity in HIV-infected people.
IL-7 is required for the development and homeostasis of T cells [5] . In HIV-infected patients, IL-7 administration induces T-cell expansions in peripheral blood and gut mucosa [6] . Notably, IL-7 dramatically enhances the function of MAIT cells from both healthy individuals and HIV-infected patients in vitro [2] . We hypothesized that in-vivo administration of IL-7 in chronically HIV-1-infected patients on ART may overcome the inability of long-term ART alone to restore MAIT cells. To address this hypothesis, we evaluated the numbers, phenotype, and functionality of MAIT cells before and after IL-7 administration.
HIV-1-infected patients with CD4 þ cell counts of 101-400 cells/ml, plasma HIV RNA less than 50 copies/ml who were on ART for at least 12 months were enrolled in a single-arm, open-label, multicenter study (NCT01190111) approved by the study sites ethics committees. HIV-uninfected individuals (n ¼ 7) were recruited at the blood bank of the National Institute of Health (NIH). All study participants provided their informed consent. Patients were treated with three subcutaneous injections of IL-7 (CYT107) at a dose of 10-mg/kg each. Peripheral blood mononuclear cells (PBMCs) were collected at baseline, before IL-7 administration, and at week 12 post-IL-7. The details of the clinical trial have been previously published [7, 8] . Seven HIV-infected men with a median age of 55 years (range 43-58 years), median CD4 þ T-lymphocyte count of 270 cells/ml (range 135-364 cells/ml) and plasma HIV RNA less than 50 copies/ml were included in this study based on sample availability. Cryopreserved PBMCs were used for immunophenotyping. The functional assays for activation of MAIT cells in the PBMC mixture with IL-12 and IL-18 or Escherichia coli (ratio E. coli colony forming units : PBMC of 3) were performed for 24 h as previously described [2] . The antibodies used were anti-CD4 þ APC-Cy7, anti-CD3 Samples were acquired on an LSRII flow cytometer (BD Biosciences). Software-based compensation was performed using the compensation platform in FlowJo software versions 9.9 and 10.0.8 (FlowJo, LLC, Ashland, Oregon, USA).
The Wilcoxon signed-rank test was used to assess significance. Statistical analyses were performed using Prism version 7.0a (GraphPad, La Jolla, California, USA) and two-sided P values less than 0.05 were considered significant. [4] ; however, the difference did not reach statistical significance. We evaluated the percentage and absolute number of MAIT cells from baseline to week 12 post-IL-7 treatment (Fig. 1a) . The percentage of MAIT cells among total lymphocytes increased significantly [median (IQR) ¼ 1.2% (0.1-1.5) vs. 0.3% (0.1-0.7), P ¼ 0.01] (Fig. 1b) . As IL-7 expands overall T cells in HIV-infected persons [ population trended toward an increase, although the change did not reach statistical significance [median (IQR) ¼ 1.3% (0.27-2.12) vs. 0.5% (0.2-1.2), P ¼ 0.1] (Fig. 1c) . However, the absolute number of MAIT cells increased significantly at 12 weeks post-IL-7 administration compared with baseline [median (IQR) 22 (6-75.9) vs. 5.2 (4.2-12.9) cells/ml, P ¼ 0.01] (Fig. 1d) . Furthermore, the absolute number of CD8 þ MAIT cells increased after IL-7 treatment [median (IQR) 20.5 (4-33.5) vs. 4 (2-11) cells/ml, P ¼ 0.01] (Fig. 1e) .
It was previously reported that MAIT cells have reduced expression of transcription factors T-bet and EOMES in chronically HIV-infected individuals, and this was associated with loss of MAIT cells in the periphery and impaired effector function [2] . In the same study, addition of IL-7 to MAIT cells in vitro enhanced their effector responses to bacterial stimulation [2] . Due to limited sample availability, we were only able to test responses to E. coli stimulation in one patient, and MAIT cells in this patient maintained responsiveness and effector function after IL-7 treatment (Fig. 1f) .
Although we did not study MAIT cells in mucosal samples, this will be of interest for future studies to evaluate the potential significance of increased MAIT cells in mucosal immunity.
In conclusion, we found a significant increase in the frequency and number of MAIT cells in the periphery of chronically HIV-infected individuals 12 weeks post-IL-7 treatment. This is striking, given that no significant restoration of MAIT cells has been seen during long-term ART [4] . 
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